Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.
Curr Pharm Biotechnol
; 25(15): 2001-2011, 2024.
Article
in En
| MEDLINE
| ID: mdl-38310449
ABSTRACT
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has emerged as a revolutionary approach for cancer treatment, especially for hematologic cancers. However, CAR-T therapy has some limitations, including cytokine release syndrome (CRS), immune cellassociated neurologic syndrome (ICANS), and difficulty in targeting solid tumors and delivering allogeneic cell therapy due to graft-versus-host disease (GvHD). Therefore, it is important to explore other cell sources for CAR engineering. Invariant natural killer T (iNKT) cells are a potential target, as they possess powerful antitumor ability and do not recognize mismatched major histocompatibility complexes (MHCs) and protein antigens, thus avoiding the risk of GvHD. CAR-engineered iNKT (CAR-iNKT) cell therapy offers a promising new approach to cancer immunotherapy by overcoming the drawbacks of CAR-T cell therapy while retaining potent antitumor capabilities. This review summarizes the current CAR-iNKT cell products, their functions and phenotypes, and their potential for off-the-shelf cancer immunotherapy.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Natural Killer T-Cells
/
Tumor Microenvironment
/
Receptors, Chimeric Antigen
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Curr Pharm Biotechnol
Journal subject:
BIOTECNOLOGIA
/
FARMACOLOGIA
Year:
2024
Type:
Article
Affiliation country:
United States